07:00 , May 4, 2009 |  BC Week In Review  |  Company News

NicOx, Deerfield Management deal

NicOx acquired from Deerfield's Nitromed Inc. unit unlicensed IP covering nitric oxide (NO)-donating compounds for € 2 million ($2.6 million). NitroMed is eligible to receive an additional € 4 million ($5.3 million) upon NicOx fulfilling...
07:00 , Apr 30, 2009 |  BC Innovations  |  Distillery Therapeutics

Indication: Cardiovascular disease

This week in therapeutics Indication Target/marker/ pathway Summary Licensing status Publication and contact information Cardiovascular disease Cardiac hypertrophy; heart failure Calcium calmodulin-dependent kinase IIδ (CAMK2D); ryanodine receptor 2 (RyR2) Studies in mice suggest that targeting...
08:00 , Feb 2, 2009 |  BC Week In Review  |  Company News

Archemix, NitroMed, Deerfield Management, JHP Pharmaceuticals LLC deal

NitroMed agreed to be acquired by Deerfield for $0.80 per share in cash, valuing the biotech at $36.9 million. The price is a 25% premium to NitroMed's close of $0.64 on Jan. 26, before the...
08:00 , Feb 2, 2009 |  BioCentury  |  Finance

Ebb & Flow

Two separate takeouts involving NitroMed (NASDAQ:NTMD) and Exact Sciences (NASDAQ:EXAS) were upset last week, and a third deal involving Progen (ASX:PGL; NASDAQ:PGLA) was threatened, all by third parties that have their own ideas about what...
02:19 , Jan 28, 2009 |  BC Extra  |  Company News

NitroMed agrees to new Deerfield offer

NitroMed (NASDAQ:NTMD) agreed to be acquired by Deerfield Management for $0.80 per share in cash. The price would value NitroMed at $36.9 million based on 46.1 million shares outstanding and is a 25% premium to...
08:00 , Jan 19, 2009 |  BC Week In Review  |  Company News

NitroMed, Deerfield Management deal

Deerfield revised its offer to acquire NitroMed twice last week. On Jan. 9, Deerfield increased its offer to acquire NitroMed from $0.50 to $0.65 per share in cash. Subsequently, on Jan. 14, NitroMed announced a...
02:22 , Jan 13, 2009 |  BC Extra  |  Company News

NitroMed up on raised offer from Deerfield

NitroMed (NASDAQ:NTMD) gained $0.10 (25%) to $0.50 on Monday after announcing Deerfield Management increased its proposal to acquire the biotech to $0.65 from $0.50 per share in cash. The price would value NitroMed at $30...
08:00 , Jan 12, 2009 |  BioCentury  |  Strategy

Architecting Archemix's cash

Archemix Corp. says its discovery deal with GlaxoSmithKline plc won't affect the biotech's plans to reverse-merge with NitroMed Inc. Indeed, having the $27.5 million upfront fee in the bank and more coverage of its outlays...
08:00 , Dec 8, 2008 |  BC Week In Review  |  Company News

NitroMed, Deerfield Management deal

Deerfield made an unsolicited offer to acquire NitroMed for $0.50 per share in cash. The price would value NitroMed at $23 million based on 46 million shares outstanding and is a 67% premium to NitroMed's...
08:00 , Dec 8, 2008 |  BioCentury  |  Finance

Ebb & Flow

With capital markets tight, biotech companies are looking for non-dilutive ways to guarantee access to new funds should they need them. Last week, Micromet (NASDAQ:MITI) and Newron (SWX:NWRN) both secured equity agreements that provide them...